Tatsuo Kuroda

Dr. Tatsuo Kuroda


Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2017 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
MOMichinobu Ohno
Michinobu Ohno
YFYasushi Fuchimoto
Yasushi Fuchimoto
HHHuai-Che Hsu
Huai-Che Hsu
MHMasataka Higuchi
Masataka Higuchi
MKMakoto Komura
Makoto Komura
TKTatsuo Kuroda
Tatsuo Kuroda

18 September 2014 in Cytotechnology
Verified
Journal Article
Open access
PDF file
RNRyuhei Nishikawa
Ryuhei Nishikawa
RHRyo Hotta
Ryo Hotta
NSNaoki Shimojima
Naoki Shimojima
SSShinsuke Shibata
Shinsuke Shibata
NNNarihito Nagoshi
Narihito Nagoshi
YMYasuhide Morikawa
Yasuhide Morikawa
Stem cell therapy offers the potential of rebuilding the enteric nervous system (ENS) in the aganglionic bowel of patients with Hirschsprung’s disease. P0-Cre/Floxed-EGFP mice in which neural crest-derived cells express EGFP were used to obtain ENS stem/progenitor cells. ENS stem/progenitor cells were transplanted into the bowel of Ret−/− mouse, an animal model of Hirschsprung’s disease. Immunohistochemical analysis was performed to determine whether grafted cells gave rise to neurons in the recipient bowel. EGFP expressing neural crest-derived cells accounted for 7.01 ± 2.52 % of total cells of gastrointestinal tract. ENS stem/progenitor cells were isolated using flow cytometry and expanded as neurosphere-like bodies (NLBs) in a serum-free culture condition. Some cells in NLBs expressed neural crest markers, p75 and Sox10 and neural stem/progenitor cells markers, Nestin and Musashi1. Multipotency of isolated ENS stem/progenitor cells was determined as they differentiated into neurons, glial cells, and myofibloblasts in culture. When co-cultured with explants of hindgut of Ret−/− mice, ENS stem/progenitor cells migrated into the aganglionic bowel and gave rise to neurons. ENS stem/progenitor cells used in this study appear to be clinically relevant donor cells in cell therapy to treat Hirschsprung’s disease capable of colonizing the affected bowel and giving rise to neurons.

27 January 2020 in Neurogastroenterology & Motility
Verified
Journal Article
Open access
PDF file
NSNaoki Shimojima
Naoki Shimojima
MKMasakuni Kobayashi
Masakuni Kobayashi
SKShunsuke Kamba
Shunsuke Kamba
AHAtsushi Harada
Atsushi Harada
SHSeiichi Hirobe
Seiichi Hirobe
KSKazuki Sumiyama
Kazuki Sumiyama
Background: Hirschsprung's disease is a congenital abnormality of the enteric nervous system (ENS) presenting severe constipation soon after birth due to the lack of ganglion cells in the distal gut. Surgery for Hirschsprung's disease requires an intraoperative histopathological diagnosis to assess the extent of aganglionosis. Confocal laser endomicroscopy (CLE) is a novel endoscopic technique allowing real‐time, in vivo analysis of cellular details during ongoing endoscopy. In this study, we evaluated the possibility of a new application of CLE to provide real‐time observations of the ENS in patients with Hirschsprung's disease. In this preclinical feasibility study, we assessed the visualization of the ENS by CLE using surgically resected intestines.Methods: The subjects were nine patients who underwent pull‐through surgery for Hirschsprung's disease between September 2014 and March 2016. The colon specimens were stained with 0.1% cresyl violet and evaluated using CLE. We compared the CLE findings with those of the histopathological examination.Key Results: The ENS was clearly visualized as a ladder‐like structure in the ganglionic segment but was not observed in the aganglionic segment. Of the 69 samples, corresponding positive and negative results for both CLE and the histopathology were obtained in 61 (88%). In addition, CLE was able to visualize unique, wavy structures comprising thick nerve bundles characteristic of the aganglionic/transition zone in Hirschsprung's disease.Conclusions and Inferences: As a novel tool for visualizing the human ENS, CLE has the potential to revolutionize how pediatric surgeons identify the level of ganglionosis during surgery for Hirschsprung's disease and may be a superior alternative to intraoperative histopathological diagnosis.

7 August 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
YKYumi Kudo
Yumi Kudo
KMKentaro Miyamoto
Kentaro Miyamoto
SSShohei Suzuki
Shohei Suzuki
ACAkihiko Chida
Akihiko Chida
ATAnna Tojo
Anna Tojo
TSTomohisa Sujino
Tomohisa Sujino
BACKGROUND: Glucagon-like peptide-2 (GLP-2) analogs are used clinically to enhance nutrient absorption in patients with short bowel syndrome (SBS); however, the precise mechanism remains unclear. To address this, the study aimed to clarify the dynamics of intestinal epithelial cells and immune cells in patients with SBS treated with GLP-2 analogs. METHODS: Five male patients diagnosed with SBS, all of whom received treatment with the GLP-2 analog teduglutide, were included in the study. We conducted longitudinal single-cell RNA sequencing (scRNA-Seq) analysis of intestinal tissue from patients with SBS over a year, integrating microbiome composition analysis. RESULTS: After treatment, the α-diversity of the gut microbiome increased, indicating a more varied microbial environment. ScRNA-Seq analysis revealed a reduction of T helper 2 cells and an increase in regulatory T cells, suggesting a shift toward an immunoregulatory intestinal environment. Additionally, nutrient-absorbing enterocyte-Top2 and middle clusters expanded, enhancing the absorption capacity, whereas major histocompatibility complex class I/II–expressing enterocyte-Top1 cells declined, potentially modulating immune responses. CONCLUSION: The study findings indicate that GLP-2 analogs reshape intestinal immunity and microbiota, fostering a less inflammatory environment while promoting nutrient uptake efficiency. These insights offer a deeper understanding of the role of GLP-2 analogs in gut adaptation and provide a foundation for refining clinical strategies for SBS treatment. FUNDING: This work was supported by Sakaguchi Memorial Foundation, Grants-in-Aid from the Japanese Society for the Promotion of Science (JSPS) (21K18272, 23H03665, 23H02899, 23K27590, 25K22627, 23K08037), JST FOREST(21457195), and the Takeda Japan Medical Office Funded Research Grant 2022.

4 March 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TFTakumi Fujimura
Takumi Fujimura
SSShinsuke Shibata
Shinsuke Shibata
NSNaoki Shimojima
Naoki Shimojima
YMYasuhide Morikawa
Yasuhide Morikawa
Hideyuki OkanoHideyuki Okano
Hideyuki Okano
TKTatsuo Kuroda
Tatsuo Kuroda
Gastrointestinal motility disorders, severe variants in particular, remain a therapeutic challenge in pediatric surgery. Absence of enteric ganglion cells that originate from neural crest cells is a major cause of dysmotility. However, the limitations of currently available animal models of dysmotility continue to impede the development of new therapeutics. Indeed, the short lifespan and/or poor penetrance of existing genetic models of dysmotility prohibit the functional evaluation of promising approaches, such as stem cell replacement strategy. Here, we induced an aganglionosis model using topical benzalkonium chloride in a P0-Cre/GFP transgenic mouse in which the neural crest lineage is labeled by green fluorescence. Pathological abnormalities and functional changes in the gastrointestinal tract were evaluated 2–8 weeks after chemical injury. Laparotomy combined with fluorescence microscopy allowed direct visualization of the enteric neural network in vivo. Immunohistochemical evaluation further confirmed the irreversible disappearance of ganglion cells, glial cells, and interstitial cell of Cajal. Remaining stool weight and bead expulsion time in particular supported the pathophysiological relevance of this chemically-induced model of aganglionosis. Interestingly, we show that chemical ablation of enteric ganglion cells is associated with a long lifespan. By combining genetic labeling of neural crest derivatives and chemical ablation of enteric ganglion cells, we developed a newly customized model of aganglionosis. Our results indicate that this aganglionosis model exhibits decreased gastrointestinal motility and shows sufficient survival for functional evaluation. This model may prove useful for the development of future therapies against motility disorders.

14 June 2014 in Transplantation Proceedings
Verified
Journal Article
Closed access
MSM. Shinoda
M. Shinoda
MTM. Tanabe
M. Tanabe
OIOsamu Itano
Osamu Itano
HOH. Obara
H. Obara
MKMinoru Kitago
Minoru Kitago
YKYuko Kitagawa
Yuko Kitagawa